Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kanuka Oil Serum is a topical investigational botanical drug developed by Hikurangi Bioactives Limited Partnership (HBLP) for the treatment of acne vulgaris. The active ingredient is kānuka oil (at a 3% concentration), a natural essential oil extracted from the kānuka tree (*Kunzea ericoides*), which is native to New Zealand and has a history of traditional use in Rongoā Māori (Māori traditional healing) for inflammatory conditions. The serum's proposed mechanism of action is based on the anti-inflammatory and anti-bacterial properties of kānuka oil, which are thought to help address the symptoms of acne. Key chemical markers of kānuka oil include α-pinene and viridiflorol. The drug is being evaluated in a Phase 2 double-blind randomized vehicle-controlled trial in New Zealand, where it is applied topically twice daily for 12 weeks in adults with acne vulgaris.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kanuka Oil Serum.